Russia to face shortages of some important antibiotics next year

29 December 2023

Russia may be faced with a shortage of some important antibiotics next year due to the recent decision of some global drugmakers to withdraw them from the market, The Pharma Letter’s local correspondent reports.

For example, the Japanese drugmaker Astellas Pharma (TYO: 4503) has recently decided to stop production of its antibiotic Wilprafen (josamycin) in Russia and withdraw it from the local market. So far, the Russian Ministry of Health has proposed to replace it with azithromycin, although there is a possibility that patients may be resistant to the latter due to its use during the covid-19 pandemic.

With regard to Astellas, most Russian analysts were surprised with the company’s latest decision to withdraw Wilprafen from the local market due to its status as one of the best-selling drugs in its category.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical